. Author manuscript; available in PMC: 2018 Jan 1.

Published in final edited form as: Arthritis Care Res (Hoboken). 2016 Nov 21;69(1):5–11. doi: 10.1002/acr.22992

Table 1.

Baseline Demographics of Participants with SLE and controls

	SLE Cases N=149	Controls N=126	p value

Traditional CVD Risk Factors
Age (years), mean (SD)	48.6 (10.1)	52.2 (10.1)	0.003
African American, n (%)	42 (28.2%)	27 (21.4%)	0.290
Body Mass Index (kg/m²), mean (SD)	28.4 (8.1)	29.8 (10.9)	0.260
Current Smoker, n (%)	10 (6.8%)	8 (6.4%)	0.890
Systolic Blood Pressure (mmHg), mean (SD)	114.0 (15.1)	118.9 (15.7)	0.010
Hypertension, n (%)	86 (58.7%)	40 (31.8%)	<.0001
Diabetes, n (%)	10 (6.7%)	1 (0.79%)	0.013
Total cholesterol: HDL ratio, mean (SD)	3.69 (1.42)	3.54 (1.05)
Statin use, n (%)	29 (19.5%)	17 (13.5%)	0.186
Aspirin use, n (%)	37 (24.8%)	19 (15.1%)	0.045
Prednisone use, n (%)	56 (37.6%)	N/A	N/A
Prednisone dose (mg), mean (SD)^*	12.06 (8.66)	N/A	N/A
Serum creatinine (mg/dL), mean (SD)	0.93 (1.16)	0.75 (0.13)	0.053
SLE-Related Factors
SLICC/ACR-DI, mean (SD)	2.7 (3.3)	N/A	N/A
SLEDAI-2K, mean (SD)	2.3 (2.3)	N/A	N/A
Depression-related factors
CES-D ≥ 16, n (%)	43 (28.9%)	14 (11.1%)	<0.001

Of 56 patients taking prednisone at baseline visit